Table 3.
Comparison of PM/Scl-100 antibody-positive versus-negative patients
| Disease manifestation | anti-PM/Scl-100-positive (n = 20) |
anti-PM/Scl-100-negative (n = 261) |
P value | Sensitivity, percentagea | Specificity, percentageb |
| Digital ulcersc | 12 (60.0) | 100 (38.5) | 0.095 | 10.7 | 95.2 |
| Lung fibrosisc | 11 (55.0) | 87 (33.5) | 0.086 | 11.2 | 95.1 |
| CK elevationc | 7 (35.0) | 30 (11.5) | 0.009 | 18.9 | 94.7 |
| Esophago-gastral involvementc | 11 (55.0) | 204 (78.5) | 0.026 | 5.1 | 86.2 |
| Small intestinal involvementc | 3 (15.0) | 100 (38.5) | 0.052 | 2.9 | 90.4 |
| Colon involvementc | 4 (20.0) | 115 (44.2) | 0.037 | 3.4 | 90.1 |
Clinical differences between antibody-positive and -negative patients were shown only when P values of below 0.1 were detected. a,bCalculations of sensitivity and specificity are analogous to those in Table 2. cValues displayed are numbers of patients (percentages). CK, creatine kinase.